8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):    July 13, 2009

Medizone International, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Nevada

(State of Other Jurisdiction of Incorporation)

002-93277-D

 87-0412648

(Commission File Number)

(IRS Employer Identification No.)

144 Buena Vista, P.O. Box 742, Stinson Beach, California

    94970

(Address of Principal Executive Offices)

(Zip Code)

(415) 868-0300

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Item 7.01

Regulation FD Disclosure.

On July 13, 2009, Medizone International, Inc. (“the Company”) issued a press release announcing that it has filed a patent application for the Company’s lead product AsepticSureÔ.

A copy of the press release is furnished herewith as Exhibit 99 to this Current Report on Form 8-K and is incorporated herein by reference.  The Company will also post this document on its corporate website, www.medizoneint.com, under the "Press Releases" link.

In accordance with General Instruction B.2 of Form 8-K, the information in this section of this Report shall not be deemed filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing.

Item 9.01.  Financial Statements and Exhibits.

(d)

Exhibits.  

99

Press Release dated July 13, 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medizone International, Inc.

Date: July 13, 2009

By:  /s/ Edwin G. Marshall

     -----------------------------------------------

Edwin G. Marshall

Chief Executive Officer

2

EX-99

Exhibit 99 to Form 8-k dated July 13, 2009

MEDIZONE INTERNATIONAL, INC.

San Francisco, California July 13, 2009, Medizone International, Inc. (MZEI.PK)

Has filed for patent protection for its AsepticSureÔ hospital sterilization system.  Following months of engineering development and laboratory research Medizone has filed what it believes to be a very solid patent application for the Company’s lead product AsepticSureÔ.  Medizone’s CEO Edwin Marshall stated, “This U.S. priority patent application establishes protection of our commercial rights to this technology Internationally.  We had two different firms specializing in patent law independently research the existing art in this area so that we had a clear understanding on how to proceed from the beginning.  Fortunately, the creative work done by our science and engineering teams has proven these new and innovative combinations of technology when combined have greatly enhanced bactericidal kill rates with all of the pathogens tested so far.  This is not just pum ping ozone gas into a room.  This patent filing not only identifies a number of unique technologies and their protocols, it provides the scientific data proving our ability to obtain 4.4 log/99.994% to 5 log/99.999% kill rates for all of the pathogens of concern in hospital acquired infections.  This patent covers disinfection for rooms and their contents within all healthcare facilities, mobile or stationary, and other critical infrastructure such as schools and government buildings.  Even as the Company prepares to move into hospital testing later this year, we will continue to work in our new laboratory gaining additional knowledge not only about the pathogens we have already demonstrated outstanding success with, but against a long list of other agents that might provide the Company with significant commercial advantage as we advance the science and practical application of AsepticSureÔ beyond the hospital environment.”

Medizone International, Inc., is a research and development company engaged in developing its

AsepticSure™ technology to decontaminate and sterilize hospital surgical suites, emergency rooms,

intensive care units, schools and other critical infrastructure. Current trials will now be expanded to include

a hospital mock-up and then hospital beta testing of the production prototype.  Initial sales are currently targeted to commence by the end of this year.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

Investor Relations: 800-953-3350 / web site: www.medizoneint.com

E-mail: operations @ medizoneint.com